10 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Low-risk gestational trophoblastic neoplasia is the mild form of this rare pregnancy-related cancer, usually found when the pregnancy hormone hCG fails to fall after removal of a molar pregnancy. It is cured in almost every woman with a single chemotherapy drug, methotrexate or actinomycin D, given until the hormone level is normal, and most go on to have normal pregnancies afterwards.
Gestational trophoblastic neoplasia arises from the placental trophoblast of a pregnancy, most often a complete or partial hydatidiform mole, and is unique among cancers in producing a near-perfect tumour marker, human chorionic gonadotropin (hCG), which is used for diagnosis, staging, monitoring and follow-up. After evacuation of a complete mole 15 to 20 percent of women, and after a partial mole 0.5 to 5 percent, develop neoplasia (the FIGO 2021 report's ranges), detected by a plateau or rise in serial hCG without any need for biopsy. The FIGO 2000 scoring system combines age, antecedent pregnancy, interval, hCG level, tumour size, site and number of metastases and prior chemotherapy into a score; 6 or below is low risk and predicts response to single-agent chemotherapy. Low-risk disease is typically an invasive mole or choriocarcinoma confined to the uterus or with small lung metastases.
Single-agent chemotherapy cures nearly all patients. Methotrexate, whose effect on choriocarcinoma Hertz, Li and Spencer reported in 1956, is given as an eight-day regimen alternating with folinic acid (the Charing Cross schedule) or weekly, and actinomycin D as a pulsed fortnightly dose; the GOG 174 trial (Journal of Clinical Oncology 2011) found pulsed actinomycin D produced more complete responses than weekly intramuscular methotrexate (70 against 53 percent of 216 eligible women), though methotrexate remains first choice in many centres for its low toxicity. Treatment continues until hCG is normal and then for two to three consolidation cycles, and women who develop resistance switch to the other single agent or, if hCG is high, to multi-agent EMA-CO; overall survival in low-risk disease is close to 100 percent whatever the sequence. A second curettage cured 40 percent of 60 women with non-metastatic low-risk disease in a Gynecologic Oncology Group phase 2 study (2016), and hysterectomy is an option for women who have completed their families. Because trophoblast expresses PD-L1, the anti-PD-L1 antibody avelumab normalised hCG in eight of fifteen women whose disease had resisted single-agent chemotherapy in cohort A of the TROPHIMMUN trial (Journal of Clinical Oncology 2020), with no relapses; the FIGO 2021 report notes that this is lower than second-line actinomycin D achieves and does not recommend avelumab as standard salvage in low-risk disease. In the single-arm TROPHAMET phase 1/2 trial (JAMA Oncology 2026), avelumab given with first-line methotrexate normalised hCG in 96 percent of 26 assessable women, with no relapses at a median 41 months and no comparison arm. Follow-up hCG monitoring continues for at least a year and pregnancy is deferred until it is complete; subsequent pregnancies are normal in most cases, with a small risk of a further mole.
| Setting | Approach | Guideline |
|---|---|---|
| Diagnosis and staging | Serial hCG after molar evacuation; pelvic Doppler ultrasound and chest X-ray or CT; FIGO scoring; no biopsy needed. | not mapped |
| First line | Single-agent methotrexate with folinic acid (eight-day regimen) or pulsed actinomycin D (GOG 174), continued until hCG normalises plus three consolidation cycles. | not mapped |
| Resistance to first agent | Switch to the alternative single agent if hCG is low; EMA-CO if hCG is high; avelumab studied as a chemotherapy-sparing option (TROPHIMMUN cohort A: hCG normalised in 8 of 15), though the FIGO 2021 report does not recommend it as standard salvage. | not mapped |
| Surgery | Second uterine evacuation in selected women with low hCG; hysterectomy for women who have completed their families or with uncontrolled bleeding. | not mapped |
| Follow-up | hCG monitoring for twelve months after remission, contraception during follow-up, and hCG after every future pregnancy. | not mapped |